149 related articles for article (PubMed ID: 16806969)
1. Protein expression and preliminary crystallographic analysis of amino-terminal fragment of urokinase-type plasminogen activator.
Zhao G; Yuan C; Bian C; Hou X; Shi X; Ye X; Huang Z; Huang M
Protein Expr Purif; 2006 Sep; 49(1):71-7. PubMed ID: 16806969
[TBL] [Abstract][Full Text] [Related]
2. Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143).
Huang M; Mazar AP; Parry G; Higazi AA; Kuo A; Cines DB
Acta Crystallogr D Biol Crystallogr; 2005 Jun; 61(Pt 6):697-700. PubMed ID: 15930623
[TBL] [Abstract][Full Text] [Related]
3. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
[TBL] [Abstract][Full Text] [Related]
4. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
[TBL] [Abstract][Full Text] [Related]
5. Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites.
Gårdsvoll H; Werner F; Søndergaard L; Danø K; Ploug M
Protein Expr Purif; 2004 Apr; 34(2):284-95. PubMed ID: 15003263
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activator.
Crippa MP
Int J Biochem Cell Biol; 2007; 39(4):690-4. PubMed ID: 17118695
[TBL] [Abstract][Full Text] [Related]
7. [Biological function of fusion protein ATF-PAI2CD].
Wang X; Li P; Zhang YQ; Hou M; Sun XH; Tan L; Zhu YS
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Jul; 35(7):624-8. PubMed ID: 12883632
[TBL] [Abstract][Full Text] [Related]
8. Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor.
Nagase K; Kobayashi H; Yoshikawa E; Kurita N
J Mol Graph Model; 2009 Aug; 28(1):46-53. PubMed ID: 19403319
[TBL] [Abstract][Full Text] [Related]
9. One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry.
Jacobsen B; Gårdsvoll H; Juhl Funch G; Ostergaard S; Barkholt V; Ploug M
Protein Expr Purif; 2007 Apr; 52(2):286-96. PubMed ID: 17027282
[TBL] [Abstract][Full Text] [Related]
10. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
Salasznyk RM; Zappala M; Zheng M; Yu L; Wilkins-Port C; McKeown-Longo PJ
Matrix Biol; 2007 Jun; 26(5):359-70. PubMed ID: 17344041
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of interaction between urokinase-type plasminogen activator and its receptor.
Barinka C; Parry G; Callahan J; Shaw DE; Kuo A; Bdeir K; Cines DB; Mazar A; Lubkowski J
J Mol Biol; 2006 Oct; 363(2):482-95. PubMed ID: 16979660
[TBL] [Abstract][Full Text] [Related]
12. Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor.
Kamiyama H; Zhou G; Roizman B
Gene Ther; 2006 Apr; 13(7):621-9. PubMed ID: 16292350
[TBL] [Abstract][Full Text] [Related]
13. Does the urokinase receptor exist in a latent form?
Yuan C; Huang M
Cell Mol Life Sci; 2007 May; 64(9):1033-7. PubMed ID: 17372678
[TBL] [Abstract][Full Text] [Related]
14. Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 replication.
Wada M; Wada NA; Shirono H; Taniguchi K; Tsuchie H; Koga J
Biochem Biophys Res Commun; 2001 Jun; 284(2):346-51. PubMed ID: 11394884
[TBL] [Abstract][Full Text] [Related]
15. Crystallization and X-ray diffraction data of the cleaved form of plasminogen activator inhibitor-1.
Aertgeerts K; De Bondt HL; De Ranter C; Declerck PJ
Proteins; 1995 Sep; 23(1):118-21. PubMed ID: 8539244
[TBL] [Abstract][Full Text] [Related]
16. Expression, purification, and crystallization and preliminary X-ray crystallographic analysis of CnrX from Cupriavidus metallidurans CH34.
Kim KH; Jung EJ; Im H; Lelie DV; Kim EE
J Microbiol Biotechnol; 2008 Jan; 18(1):43-7. PubMed ID: 18239414
[TBL] [Abstract][Full Text] [Related]
17. Crystallization and preliminary X-ray analysis of neuropsin, a serine protease expressed in the limbic system of mouse brain.
Kishi T; Kato M; Shimizu T; Kato K; Matsumoto K; Yoshida S; Shiosaka S; Hakoshima T
J Struct Biol; 1997 Apr; 118(3):248-51. PubMed ID: 9169235
[TBL] [Abstract][Full Text] [Related]
18. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
[TBL] [Abstract][Full Text] [Related]
19. Expression, purification, and biological characterization of the amino-terminal fragment of urokinase in Pichia pastoris.
Li J; Lin Y; Zhuang H; Hua ZC
J Microbiol Biotechnol; 2013 Sep; 23(9):1197-205. PubMed ID: 23751561
[TBL] [Abstract][Full Text] [Related]
20. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
Sprague LD; Tomaso H; Mengele K; Schilling D; Bayer C; Stadler P; Schmitt M; Molls M
Oncol Rep; 2007 May; 17(5):1259-68. PubMed ID: 17390074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
